Exelixis (EXEL) to Release Earnings on Wednesday

Exelixis (NASDAQ:EXEL) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.86 per share and revenue of $636.3730 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 earnings per share. On average, analysts expect Exelixis to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Exelixis Stock Performance

Shares of EXEL stock opened at $56.51 on Wednesday. Exelixis has a fifty-two week low of $33.76 and a fifty-two week high of $57.57. The company has a 50 day moving average price of $53.44 and a 200 day moving average price of $47.38. The stock has a market capitalization of $14.20 billion, a P/E ratio of 18.77, a price-to-earnings-growth ratio of 1.61 and a beta of 0.42.

Insider Transactions at Exelixis

In related news, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares in the company, valued at $29,945,209.35. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares of the company’s stock, valued at $17,813,948.78. This trade represents a 8.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 219,170 shares of company stock valued at $10,620,641 over the last quarter. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Exelixis

Institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after buying an additional 4,477,029 shares during the last quarter. UBS Group AG raised its stake in Exelixis by 100.1% in the third quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock valued at $109,654,000 after buying an additional 1,328,087 shares in the last quarter. Morgan Stanley lifted its holdings in Exelixis by 31.0% during the 4th quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock worth $184,378,000 after buying an additional 995,949 shares during the last quarter. Bank of America Corp DE lifted its holdings in Exelixis by 38.2% during the 2nd quarter. Bank of America Corp DE now owns 2,638,666 shares of the biotechnology company’s stock worth $116,299,000 after buying an additional 728,956 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in Exelixis by 203.8% during the 4th quarter. Voloridge Investment Management LLC now owns 960,768 shares of the biotechnology company’s stock worth $42,110,000 after buying an additional 644,495 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Stifel Nicolaus raised their price target on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Citizens Jmp upped their price objective on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Wednesday, June 24th. Truist Financial upped their price objective on Exelixis from $54.00 to $56.00 and gave the stock a “hold” rating in a research report on Tuesday, July 7th. TD Cowen increased their price objective on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, UBS Group reiterated a “buy” rating on shares of Exelixis in a report on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $49.29.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.